Management of Gastric Overload in Patients Taking Semaglutide

Understanding the Risk

Semaglutide and other GLP-1 receptor agonists significantly delay gastric emptying, with multiple studies showing increased risk of retained gastric contents despite adherence to standard fasting guidelines 1, 4
Recent evidence shows 24.2% of patients on semaglutide have increased residual gastric content compared to 5.1% in control groups, even with extended fasting periods of 12+ hours 2
Prospective studies using gastric ultrasonography have demonstrated that 56% of patients taking GLP-1 receptor agonists have retained gastric contents despite complying with current fasting guidelines 3
Case reports document serious complications including pulmonary aspiration requiring ICU admission in patients who had discontinued semaglutide 4-6 days prior to procedures 4

Perform gastric ultrasound assessment when possible to identify patients with retained gastric contents, as this can detect solid food retention despite prolonged fasting 3
Be particularly vigilant in patients with pre-existing digestive symptoms, as these patients show significantly higher risk of gastric content retention when on semaglutide 2
Consider the duration of semaglutide treatment, as patients on chronic therapy (median 57 months) show higher rates of gastric residue 2

Implement extended fasting periods: 12+ hours for solids and 4+ hours for clear liquids 2, 4
For patients who cannot discontinue semaglutide sufficiently in advance, consider full stomach precautions including rapid sequence induction 4
For patients who cannot discontinue semaglutide sufficiently in advance, consider tracheal intubation rather than supraglottic airway devices 4
For patients who cannot discontinue semaglutide sufficiently in advance, consider pre-operative gastric ultrasound to assess risk 3

Patients using semaglutide for weight loss may be at particularly high risk, with studies showing 7/10 patients having solid food in the stomach after 10 hours of fasting 3
Recently initiated semaglutide therapy (within 4 weeks) may present higher risk of gastric retention 3

Do not rely solely on standard fasting guidelines, as they are insufficient for patients on semaglutide 3
Avoid assuming that short-term discontinuation (4-6 days) eliminates risk, as case reports show serious aspiration events despite this precaution 4
Remember that the risk appears to decrease with each additional day of drug discontinuation, but studies are underpowered to determine the optimal discontinuation period 3